News & Media
Follow us on our path to driving innovation for immunocompromised people
Publications
Design and In Vitro Evaluation of a Novel Antisense Oligonucleotide for Treatment of BK Virus Infection
Jurriën Prins, Janneke Kouwenberg, Anouk Spruit, Lizanne Daleman, Iris van Wissen, Bianca Matthee, Angela Koudijs, Caroline de Brouwer, Ellen Lievers, Franca Witjas, Vita Dauksaite, Carla van Alem, Roel Bijkerk, Annemieke Aartsma-Rus, Jessica Sipkens, Ton Rabelink, Mariet Feltkamp, Tamara Pfaff, Holger Zimmermann, Anton Jan van Zonneveld, Peter Lischka, and Eric van der Veer
DOI: 10.1089/nat.2025.0010
Successful treatment and secondary prophylaxis with pritelivir for a recurrent multi-drug resistant HSV-1 infection in an allogeneic hematopoietic stem cell transplant recipient
Bussini Linda, Giardina Federica A.M., Paolucci Stefania, Mannina Daniele, Birkmann Alexander, Bartoletti Michele
Clin Microbiol Infect. 2025 Apr 19:S1198-743X(25)00174-0. doi: 10.1016/j.cmi.2025.04.011
Discovery and Development of the Helicase–Primase Inhibitor Pritelivir for the Treatment of Immunocompromised Patients with Resistant HSV Infection
Alexander Birkmann
https://doi.org/10.1002/9783527845088.ch02
Overview on the management of herpes simplex virus infections: Current therapies and future directions
Alexander Birkmann, Rob Saunders
Antiviral Res.2025 May:237:106152.doi: 10.1016/j.antiviral.2025.106152
Refractory and Resistant Herpes Simplex Virus Mucocutaneous Infections in Immunocompromised Patients: Literature Review and Proposed Definitions for Use in Clinical Trials
Roy F Chemaly, Tali Shafat, Anna Wald, Camille N Kotton, Genovefa Papanicolaou, Michelle K Yong, Veronica Miller, Takashi E Komatsu, Charu Mullick , Aimee C Hodowanec, Gabriel Westman, Fareed Khawaja, Alexander Birkmann, Per Ljungman
Clin Infect Dis.2025 Jan 29:ciae638. doi: 10.1093/cid/ciae638
Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Pritelivir and Its Metabolites
Katharina Erb-Zohar, Susanne Bonsmann, Jörg Pausch, Melanie Sumner, Alexander Birkmann, Holger Zimmermann , Atef Halabi, Dirk Kropeit
Clin Pharmacol Drug Dev. 2024 Sep 25. doi: 10.1002/cpdd.1469
Pritelivir for The Treatment of Nucleoside Analogue-Resistant Orolabial Herpes Simplex Virus 2 in a Person Living with HIV
Andrew Purssell, Kennedy Leung, Pierre Giguère, Jonathan B Angel
Volume 9 Issue 2, June 2024, pp. 108-112
Evaluation Of The Clinical Drug-Drug Interaction Potential Of Pritelivir On Transporters And Cyp450 Enzymes Using A Cocktail Approach
Michiel de Vries, Susanne Bonsmann, Jörg Pausch, Melanie Sumner, Alexander Birkmann, Holger Zimmermann, Dirk Kropeit
Clin Pharmacol Drug Dev. 2024 May 16. doi/10.1002/cpdd.1408
Mass Balance and Metabolite Profile After Single and Multiple Oral Doses of Pritelivir in Healthy Subjects
Susanne Bonsmann, David McCormick, Jörg Pausch, Michiel de Vries, Melanie Sumner, Alexander Birkmann, Holger Zimmermann, Dirk Kropeit
Clin Pharmacol Drug Dev. 2024 Apr;13(4):389-403. doi: 10.1002/cpdd.1358. Epub 2024 Jan 8.
A Multi-Center Assessment of The Outcomes and Toxicities of Foscarnet for Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex in Immunocompromised Patients
Sarah P Hammond, Manickam Rangaraju, Melanie Sumner, Burkhard Timmler, Pranatharthi Chandrasekar, Robin K Avery
Open Forum Infect Dis. 2024 Feb 5;11(3):ofae046. doi: 10.1093/ofid/ofae046. eCollection 2024 Mar.